Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | KHK | P50053 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 2/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51299 | 0.98 | LOXL2 (0.47) | LOXL2TRPV4DPP4DPP8KHK | |
| SCHEMBL31126027 | 0.98 | LOXL2 (0.47) | LOXL2TRPV4DPP4DPP8KHK | |
| SCHEMBL1240018 | 0.85 | TAAR1 (0.47) | TRPV4DPP4DPP8MAOBPNMT | |
| Hydrochloric Acid SCHEMBL28802791 | 0.83 | TAAR1 (0.45) | TRPV4DPP4DPP8MAOBPNMT | |
| SCHEMBL3158141 | 0.82 | TRPV4 (0.57) | LOXL2TRPV4MAOAMAOBNSD2 | |
| SCHEMBL24872544 | 0.82 | TRPV4 (0.45) | TRPV4DPP4DPP8MAOAMAOB | |
| Hydrochloric Acid SCHEMBL21798388 | 0.81 | TRPV4 (0.55) | LOXL2TRPV4MAOAMAOBNSD2 | |
| Hydrochloric Acid SCHEMBL6778748 | 0.81 | TRPV4 (0.55) | LOXL2TRPV4MAOAMAOBNSD2 | |
| SCHEMBL13179910 | 0.80 | TRPV4 (0.44) | TRPV4DPP4DPP8MAOAMAOB | |
| SCHEMBL15018389 | 0.78 | TRPV4 (0.42) | TRPV4DPP4DPP8MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| CN-102036996-A | Bridged heterocycles as HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO | 2011-04-27 | — | — | CN | disclosed |
| EP-2280981-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | LOXL2 4191/4885TRPV4 4702/4885DPP4 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.